247 related articles for article (PubMed ID: 19255331)
1. FOXP3 expression and overall survival in breast cancer.
Merlo A; Casalini P; Carcangiu ML; Malventano C; Triulzi T; Mènard S; Tagliabue E; Balsari A
J Clin Oncol; 2009 Apr; 27(11):1746-52. PubMed ID: 19255331
[TBL] [Abstract][Full Text] [Related]
2. Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy.
Ladoire S; Arnould L; Mignot G; Coudert B; Rébé C; Chalmin F; Vincent J; Bruchard M; Chauffert B; Martin F; Fumoleau P; Ghiringhelli F
Breast Cancer Res Treat; 2011 Jan; 125(1):65-72. PubMed ID: 20229175
[TBL] [Abstract][Full Text] [Related]
3. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
[TBL] [Abstract][Full Text] [Related]
4. FOXP3 expression is related to high Ki-67 index and poor prognosis in lymph node-positive breast cancer patients.
Kim MH; Koo JS; Lee S
Oncology; 2013; 85(2):128-36. PubMed ID: 23948758
[TBL] [Abstract][Full Text] [Related]
5. A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer.
Aruga T; Suzuki E; Saji S; Horiguchi S; Horiguchi K; Sekine S; Kitagawa D; Funata N; Toi M; Sugihara K; Kuroi K
Oncol Rep; 2009 Aug; 22(2):273-8. PubMed ID: 19578766
[TBL] [Abstract][Full Text] [Related]
6. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer.
Foekens JA; Atkins D; Zhang Y; Sweep FC; Harbeck N; Paradiso A; Cufer T; Sieuwerts AM; Talantov D; Span PN; Tjan-Heijnen VC; Zito AF; Specht K; Hoefler H; Golouh R; Schittulli F; Schmitt M; Beex LV; Klijn JG; Wang Y
J Clin Oncol; 2006 Apr; 24(11):1665-71. PubMed ID: 16505412
[TBL] [Abstract][Full Text] [Related]
7. Two distinct local relapse subtypes in invasive breast cancer: effect on their prognostic impact.
Casalini P; Carcangiu ML; Tammi R; Auvinen P; Kosma VM; Valagussa P; Greco M; Balsari A; Ménard S; Tagliabue E
Clin Cancer Res; 2008 Jan; 14(1):25-31. PubMed ID: 18172248
[TBL] [Abstract][Full Text] [Related]
8. Prognostic relevance of proliferative activity evaluated by Mib-1 immunostaining in node negative breast cancer.
Neri A; Marrelli D; Pedrazzani C; Caruso S; De Stefano A; Mariani F; Megha T; De Marco G; Corso G; Pinto E; Roviello F
Eur J Surg Oncol; 2008 Dec; 34(12):1299-303. PubMed ID: 18164172
[TBL] [Abstract][Full Text] [Related]
9. Impact of BCL2 and p53 on postmastectomy radiotherapy response in high-risk breast cancer. A subgroup analysis of DBCG82 b&c.
Kyndi M; Sørensen FB; Knudsen H; Alsner J; Overgaard M; Nielsen HM; Overgaard J
Acta Oncol; 2008; 47(4):608-17. PubMed ID: 18465329
[TBL] [Abstract][Full Text] [Related]
10. Angiogenesis as determined by computerised image analysis and the risk of early relapse in women with invasive ductal breast carcinoma.
Olewniczak S; Chosia M; Kołodziej B; Kwas A; Kram A; Domagała W
Pol J Pathol; 2003; 54(1):53-9. PubMed ID: 12817881
[TBL] [Abstract][Full Text] [Related]
11. Validation of 70-gene prognosis signature in node-negative breast cancer.
Bueno-de-Mesquita JM; Linn SC; Keijzer R; Wesseling J; Nuyten DS; van Krimpen C; Meijers C; de Graaf PW; Bos MM; Hart AA; Rutgers EJ; Peterse JL; Halfwerk H; de Groot R; Pronk A; Floore AN; Glas AM; Van't Veer LJ; van de Vijver MJ
Breast Cancer Res Treat; 2009 Oct; 117(3):483-95. PubMed ID: 18819002
[TBL] [Abstract][Full Text] [Related]
12. The AA genotype of the regulatory BCL2 promoter polymorphism ( 938C>A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients.
Bachmann HS; Otterbach F; Callies R; Nückel H; Bau M; Schmid KW; Siffert W; Kimmig R
Clin Cancer Res; 2007 Oct; 13(19):5790-7. PubMed ID: 17908970
[TBL] [Abstract][Full Text] [Related]
13. Prognostic relevance of cyclin E expression in operable breast cancer.
Potemski P; Kusińska R; Pasz-Walczak G; Piekarski JH; Watała C; Płuciennik E; Bednarek AK; Kordek R
Med Sci Monit; 2009 Feb; 15(2):MT34-40. PubMed ID: 19179977
[TBL] [Abstract][Full Text] [Related]
14. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer.
Salama P; Phillips M; Grieu F; Morris M; Zeps N; Joseph D; Platell C; Iacopetta B
J Clin Oncol; 2009 Jan; 27(2):186-92. PubMed ID: 19064967
[TBL] [Abstract][Full Text] [Related]
15. Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients.
Jansson A; Delander L; Gunnarsson C; Fornander T; Skoog L; Nordenskjöld B; Stål O
Clin Cancer Res; 2009 May; 15(10):3610-6. PubMed ID: 19401349
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors for survival in breast cancer patients who developed distant metastasis subsequent to definitive surgery.
Kuru B; Camlibel M; Dinc S; Gulcelik MA; Gonullu D; Alagol H
Singapore Med J; 2008 Nov; 49(11):904-11. PubMed ID: 19037557
[TBL] [Abstract][Full Text] [Related]
17. Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome.
Flowers A; Chu QD; Panu L; Meschonat C; Caldito G; Lowery-Nordberg M; Li BD
Surgery; 2009 Aug; 146(2):220-6. PubMed ID: 19628077
[TBL] [Abstract][Full Text] [Related]
18. Prognostic role of syncytin expression in breast cancer.
Larsson LI; Holck S; Christensen IJ
Hum Pathol; 2007 May; 38(5):726-31. PubMed ID: 17306327
[TBL] [Abstract][Full Text] [Related]
19. Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer.
de Jong RA; Leffers N; Boezen HM; ten Hoor KA; van der Zee AG; Hollema H; Nijman HW
Gynecol Oncol; 2009 Jul; 114(1):105-10. PubMed ID: 19411095
[TBL] [Abstract][Full Text] [Related]
20. Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study.
Reed J; Rosman M; Verbanac KM; Mannie A; Cheng Z; Tafra L
J Am Coll Surg; 2009 Mar; 208(3):333-40. PubMed ID: 19317993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
